Abstract
<jats:p>Parkinsons Disease (PD) is a progressive neurodegenerative disorder which significantly affects motor function, daily coordination and verbal communication. Speech-based biomarkers provide a non-invasive and scalable approach to early detection, as dysphonia is one of the earliest and most consistent clinical markers of PD. The dataset used in this study is publicly available and consists of 756 voice recordings from 252 subjects (188 with PD and 64 neurologically healthy controls) with a wide range of acoustic parameters such as Mel-Frequency Cepstral Coefficients (MFCCs), energy-based parameters, and higher-order statistical derivatives. After systematic preprocessing and z-score normalisation, five machine learning classifiers were tested: K-Nearest Neighbors (KNN), Extreme Gradient Boosting (XGBoost), Random Forest (RF), Support Vector Machine (SVM), and Naive Bayes (NB) under a subject-independent, GroupKFold cross-validation protocol. The KNN classifier performed best overall with an accuracy of 92.10%, F1 score of 94.50%, and a precision rate of 98.09%, reducing the number of false positive diagnoses. To overcome the lack of interpretability of black-box predictive models, SHapley Additive exPlanations (SHAP) were used to explain the contribution of each feature to the prediction of an individual. The most diagnostically salient acoustic biomarkers were identified as features from the SHAP analysis: std delta delta log energy, the first Mel-Frequency Cepstral Coefficient, and Tunable Q-Factor Wavelet Transform (TQWT). This work introduces a machine learning framework that is both reproducible and clinically interpretable, combining high predictive accuracy with transparent, physiologically grounded decision logic.</jats:p>